Compare DexCom, Inc. (DXCM) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Meta Platforms Inc — how do they compare? DexCom, Inc. trades at $84.88 (market cap $31.86B), while Meta Platforms Inc trades at $718.38 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 57.8× DexCom, Inc.'s market cap, and Meta Platforms Inc pays a 0.29% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Meta Platforms Inc for 127 Days on average.
| DXCM | META | |
|---|---|---|
Market Cap | $31.86B | $1.84T |
Volume | 3,607,070 | 15,887,049 |
Sector | Health | Media |
52-Week High | $92.34 | $777.59 |
52-Week Low | $54.84 | $525.72 |
Typical Hold Time | 62 Days | 127 Days |
Enterprise Value | $31.32B | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
META stock trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend per moving averages, with key support at $719 and resistance at $726. Recent financials reveal strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. The launch of the Muse Spark AI model and a $21B deal with CoreWeave highlight strategic initiatives driving investor optimism, countered by ongoing legal challenges over youth addiction.
The outlook for META remains positive with an 80% analyst buy rating and a consensus price target of $781, suggesting ~8% upside. Key opportunities include AI monetization and robust cash flow growth, while risks involve regulatory lawsuits and high capital expenditures. Investors should weigh strong profitability against legal and competitive pressures in the social media sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
